Watch Experimental therapies treating rare diseases have always faced a challenging road to reaching the people who need them. While the Food and Drug Administration has said it is moving ahead with new protocols to speed approvals, the agency has faced increased criticism in recent months that in practice it is standing in the way of getting these treatments to patients, as scientific and political pressures, and staff losses, are impacting the agency's approach to standards and regulatory